Drug Trial Radar · NCT00690443
Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia
Last checked: Nov 20, 2026Latest source record: Feb 23, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
44
Actual
Start
May 2008
Primary completion
Sep 2008
Study completion Sep 2008
Sponsor
- Lead sponsor
- Aegerion Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 4, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Evaluate the efficacy of combination therapy AEGR-733 plus atorvastatin 20 mg versus monotherapy on serum lipoproteins over 4 and 8 weeks of therapy. The primary efficacy parameter is percent change in LDL-C after 8 weeks of therapy.
Conditions
- Hypercholesterolemia
Interventions
AtorvastatinDrug
atorvastatin 20 mg tablets, daily dosing, for 8 weeks.
AEGR-733Drug
2.5 mg AEGR-733 capsules, daily dosing, 4 weeks followed by 5 mg AEGR-733 capsules, daily dosing, 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change in LDL-C After 8 Weeks of TherapyTime frame: Baseline and 8 weeks of treatment
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Linda Murray, DO - Radiant Research
Pinellas Park, Florida
Sheila Rodstein, MD
Edina, Minnesota
Dennis McCluskey, MD - Radiant Research
Mogadore, Ohio
Michele Reynolds, MD
Dallas, Texas
William Jennings, MD - Radiant Research
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.